Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Imatinib-Resistant/Intolerant CML or Ph+ ALL
NCT00384228Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in chronic myeloid leukemia (CML), Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Novartis. Started May 2005; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT00384228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384228.